In this issue: the disappearing supply of pink Migraleve in the UK, drug ingredients sourced from corn, using machine learning to accelerate diagnosis and treatment of rare diseases, and much more.
In this issue: Manufacturing personalised medicine, the economics of CAR-T treatments, AI in drug combination therapy and more.
US-based Seattle Children’s has initiated a Phase I clinical trial to treat solid tumours using chimeric antigen receptor (CAR) T-cell immunotherapy.
© Copyright Verdict Media Limited 2021
